Drugs / Oxandrolone
Oxandrolone
also known as
Oxandrin · Anavar · Lonavar · NSC-67068 · Oxandrolona · Oxandrolone ciii · Provitar · SC 11585 · +1 more
Small molecule targets AR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | OXANDROLONE | — | 2006-12-01 | fda.gov ↗ |
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03218631 | Jul → Nov 2017 | — | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT01048632 | Jul 2010 → May 2016 | nutritional deficiency disease | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00652886 | Mar 2005 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00243399 | Jul 2004 → Dec 2009 | Fanconi anemia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04090697 | Dec 2019 → Sep 2023 | hypoplastic left heart syndrome | Carelon Research | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06974526 | Nov 2025 → Apr 2027 expected | — | Science Valley Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT02047552 | Jan 2015 → Dec 2017 | anemia, disorder of iron metabolism and transport | Denver Health and Hospital Authority | Withdrawn | No outcome recorded |
| Phase 2 | NCT00004275 | Oct 1999 → Aug 2007 | Turner syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00001343 | Dec 1992 → Oct 2007 | Turner syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00675714 | Jan 2004 → Sep 2018 | — | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT00673309 | Jul 2000 → Apr 2011 | — | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05516849 | May 2022 → Aug 2023 | — | Sunnybrook Health Sciences Centre | Withdrawn | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05893069 | Jul 2023 → Dec 2027 | — | George F. Hatch | Suspended | No outcome recorded |
| Phase 4 | NCT00006167 | Jan 1998 → Aug 2000 | HIV wasting syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03091075 | Sep 2018 → Jan 2026 | rotator cuff syndrome | University of Southern California | Terminated | No outcome recorded |
| — | NCT00223769 | Jan 2004 → May 2006 | spinal cord injury | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT00027391 | Sep 2001 → Aug 2004 | muscular dystrophy, scapulohumeral | FDA Office of Orphan Products Development | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00348946 Comparator | Jul 2006 → Nov 2017 | Klinefelter syndrome | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00101361 Comparator | Aug 2005 → Dec 2008 | decubitus ulcer | US Department of Veterans Affairs | Terminated | No outcome recorded |
| Phase 3 | NCT00070148 Comparator | Mar 2004 → Aug 2007 | cancer of unknown primary site | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00029159 Comparator | Nov 1992 → Jan 2007 | Turner syndrome | Thomas Jefferson University | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxandrolone | “Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of...” NCT03218631 ↗20“Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years” NCT00029159 ↗ |
| Known as | Anavar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | Lonavar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | NSC-67068 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | Oxandrin | “Oxandrolone (Oxandrin)” NCT00070148 ↗ |
| Known as | Oxandrolona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | Oxandrolone ciii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | Provitar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | SC 11585 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Known as | Vasorome | ChEMBL registry synonym — accepted as the source's own label CHEMBL1200436 ↗ |
| Action | Activate | “induces its responses by binding to androgen receptors which modulates gene expression to increase protein synthesis” NCT05516849 ↗1“Androgen Receptor agonist” CHEMBL1200436 ↗ |
| Modality | Small molecule | “sex steroid hormone (oxandrolone)” NCT00001343 ↗ |
| Route | Oral | “oxandrolone) in the form of a pill” NCT00001343 ↗ |
| Target | AR | “Androgen Receptor agonist” CHEMBL1200436 ↗ |